- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06208878
En langsiktig oppfølgingsstudie av forsøkspersoner som mottok CRISPR CAR T-celleterapi
En langsiktig oppfølgingsstudie av pasienter med maligniteter behandlet med CRISPR CAR T celleterapi
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
-
Melbourne, Australia
- Alfred Health
-
Nedlands, Australia, 6009
- Sir Charles Gairdner
-
Richmond, Australia
- Epworth Healthcare
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Center
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret
-
-
-
-
California
-
Duarte, California, Forente stater, 91010
- City of Hope
-
Los Angeles, California, Forente stater, 90048
- Cedars Sinai
-
Stanford, California, Forente stater, 94305
- Stanford
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Yale New Haven Hospital
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Emory
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago
-
-
Kansas
-
Westwood, Kansas, Forente stater, 66205
- University of Kansas
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Washington University Saint Louis
-
-
New York
-
New York, New York, Forente stater, 10065
- MSKCC
-
The Bronx, New York, Forente stater, 10467
- Montefiore Medical Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern
-
Houston, Texas, Forente stater, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, Forente stater, 78229
- Methodist Hospital-Sarah Cannon
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- University of Utah-Huntsman Cancer Institute
-
-
-
-
-
Hamburg, Tyskland, D-20246
- University Hospital Hamburg-Eppendorf
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Beskrivelse
Inclusion Criteria:
- Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
- Must have received CRISPR CAR T cellular therapy.
Exclusion Criteria:
- There are no specific exclusion criteria.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Non Interventional
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. |
Safety and Efficacy Assessment |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
Tidsramme: 15 years
|
The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized. |
15 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The overall survival and duration of remission/response following CRISPR CAR T cellular therapy treatment
Tidsramme: 15 years
|
Overall survival will be calculated as the time between the initial dose of CRISPR CAR T cellular therapy in the parent study and death due to any cause. Duration of remission/response will be calculated as the time between the first objective response to first disease progression or death due to any cause. |
15 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CRSP-ONC-LTF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .